---
title: "Roivant President, CIO Mayukh Sukhatme disposes of USD 24.12 million in common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296284164.md"
description: "Roivant Sciences President and CIO Mayukh Sukhatme sold 664,826 common shares between August 14-18. The disposals were priced between $36.23 and $37.18 per share, accompanied by option exercises at $3.85. Following these transactions, his directly held common shares remained unchanged at 18,630,739."
datetime: "2026-08-19T01:00:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296284164.md)
  - [en](https://longbridge.com/en/news/296284164.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296284164.md)
generator: "portal-rs"
---

# Roivant President, CIO Mayukh Sukhatme disposes of USD 24.12 million in common shares

-   Roivant Sciences President and CIO Mayukh Sukhatme reported sales of 664,826 common shares on Aug. 14-18. \* Disposals priced at $36.23 to $37.18 per share, paired with option exercises at $3.85. \* Directly held common shares ended unchanged at 18,630,739. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-033637), on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md)

## Related News & Research

- [Roivant Sciences director Meghan FitzGerald disposes of USD 798,000 in common shares](https://longbridge.com/en/news/298660864.md)
- [Roivant publishes mosliciguat PHocus trial topline results presentation](https://longbridge.com/en/news/298312516.md)
- [61,200 Shares in Roivant Sciences Ltd. $ROIV Bought by VIRGINIA RETIREMENT SYSTEMS ET Al](https://longbridge.com/en/news/298705848.md)
- [ROIV: Mosliciguat showed unprecedented efficacy and safety in PH-ILD, advancing to phase 3](https://longbridge.com/en/news/298312682.md)
- [ROIV: PHocus trial data in PH-ILD and LISRAYA's launch highlight major advances and pipeline momentum](https://longbridge.com/en/news/298348190.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**